ForeverLabs
ServicesProvidersScienceMission
Schedule your free consultation

Regenerative Medicine Insights

Clinical trials, aesthetic applications, regulatory updates, research studies, and industry insights from the world of regenerative medicine

K

Latest Articles

Active Filters:
Tag: Corneal Epithelium
pFsplrAzb13AyETBi-Y-I.jpg
Clinical
Nov 27, 2025
1 min read
Web
Differentiation Induction of Human Stem Cells for Corneal Epithelial Regeneration
Loss or severe damage of the corneal epithelium (the clear, outer surface of the eye) can cause vision loss. Donor tissue for direct corneal or limbal epithelial transplantation is limited, and allogeneic grafts carry a rejection risk. Researchers are developing ways to turn a patient’s own stem cells into corneal epithelial cells for transplantation. This review summarizes what works so far with human stem cells — especially mesenchymal stem/stromal cells (MSCs) and pluripotent stem cells (ESCs
Corneal EpitheliumLimbal Stem Cell DeficiencyInduced Pluripotent Stem Cells (iPSCs)Mesenchymal stem cells

Stay in touch

Shop

Annual planLifetime planClient Login

Learn

ArticlesBlogFAQ

Careers

About usPrivacy policyPressTerms of Use

Questions

For physiciansPartner with usCareersContact us(888) 732-2375
ForeverLabs

Follow Us

FacebookXInstagramLinkedInYouTube

FDA and Stem Cell Therapies

The U.S. Food and Drug Administration (FDA) regulates stem cell therapies as biological products to ensure their safety and efficacy. The FDA requires that stem cell therapies undergo rigorous clinical trials to demonstrate safety and effectiveness before approval. Patients considering stem cell treatments should consult with their healthcare providers about FDA-approved options and be cautious of unproven therapies that have not undergone proper regulatory review.